Sobi and Biogen’s ELOCTA® (rFVIIIFc) Approved in Europe for the Treatment of Haemophilia A

Tuesday, November 24, 2015 1 min read

Key Takeaway: Sobi and Biogen’s ELOCTA® (rFVIIIFc) Approved in Europe for the Treatment of Haemophilia A

Full Press Release Details

Sobi and Biogen’s ELOCTA® (rFVIIIFc) Approved in Europe for the Treatment of Haemophilia A.